|
| VPZ (VAM) therapy | PPI (PAM) therapy | ||||
| First-line treatment | VAC | PAC | p value |
| ||
| Second-line treatment |
| LAM | RAM | p value | ||
| No. of patients enrolled | 129 | 126 |
| 323 | 141 |
|
| Age (Years) | 57.8 ± 12.1 | 58.7 ± 11.1 | 0.5205 | 60.8 ± 11.2 | 60.4 ± 11.1 | 0.8522 |
| Gender |
|
| 0.9483 |
|
| 0.2053 |
| Male | 64 | 62 |
| 151 | 76 |
|
| Female | 65 | 64 |
| 172 | 65 |
|
| BMI (kg/m2) | 22.8 ± 3.7 | 22.5 ± 3.0 | 0.4157 | 22.6 ± 2.9 | 22.1 ± 3.2 | 0.1244 |
| Endoscopic findings |
|
| 0.0835 |
|
| 0.1710 |
| No abnormality | 13 | 2 |
| 2 | 1 |
|
| Duodenal ulcer | 1 | 3 |
| 5 | 4 |
|
| Atrophic gastritis | 110 | 116 |
| 297 | 130 |
|
| Gastric ulcer | 4 | 5 |
| 19 | 6 |
|
| After ER for GC | 1 | 0 |
| 0 | 0 |
|
| Smoking (yes) | 15 | 19 | 0.4176 | 44 | 21 | 0.9101 |
| Drinking (yes) | 68 | 68 | 0.8408 | 152 | 61 | 0.4152 |
| Successful eradication | 97 | 104 |
| 261 | 127 |
|
| ITT analysis % (95% CI) | 75.2 (67.1 - 81.8) | 82.5 (75.0 - 88.2) | 0.1511 | 80.8 (76.2 - 84.7) | 90.1 (84.0 - 94.0) | 0.0131 |
| PP analysis % (95% CI) | 88.1 (80.7 - 92.9) | 95.4 (89.8 - 98.0) | 0.0826 | 92.9 (89.2 - 95.3) | 94.1 (88.7 - 97.0) | 0.6433 |
| Adverse events | 5 | 7 | 0.5266 | 8 | 4 | 0.7489 |